Hepatocellular Carcinoma in the Pediatric Population: A Population Based Clinical Outcomes Study Involving 257 Patients from the Surveillance, Epidemiology, and End Result (SEER) Database (1973–2011)
Table 6
Treatment and survival outcomes of fibrolamellar and nonfibrolamellar hepatocellular carcinoma for 63,514 adults and 257 pediatric patients from the Surveillance, Epidemiology, and End Results (SEER) database, 1973–2011.
Total
Pediatrics
Adults
value
fHCC
Non-fHCC
fHCC
Non-fHCC
fHCC
Non-fHCC
(%)
274 (0.4%)
63,497 (99.6%)
62 (24.1%)
195 (75.9%)
212 (0.3%)
63,302 (99.7%)
—
Treatment, (%)
No treatment
121 (45.1%)
45,437 (74.7%)
19 (30.6%)
99 (52.9%)
102 (49.5%)
45,338 (74.7%)
<0.001
Surgery only
133 (49.6%)
12,636 (20.8%)
41 (66.1%)
80 (42.8%)
92 (44.7%)
12,556 (20.7%)
<0.001
Radiation only
7 (2.6%)
2,452 (4.0%)
2 (3.2%)
6 (3.2%)
5 (2.4%)
2446 (4.0%)
<0.001
Both surgery and radiation
7 (2.6%)
323 (0.5%)
0 (0.0%)
2 (1.1%)
7 (3.4%)
321 (0.5%)
<0.001
Mean overall survival, (years ± SD)
9.110 ± 1.204
6.424 ± 0.866
6.016 ± 0653
2.657 ± 0.072
<0.001
Overall mortality, (%)
Alive
93 (33.9%)
11,445 (18.0%)
32 (51.6%)
56 (28.7%)
61 (28.8%)
11,389 (18.0%)
<0.001
Dead
181 (66.1%)
52,052 (82.0%)
30 (48.4%)
139 (71.3%)
151 (71.2%)
51,913 (82.0%)
<0.001
Cancer specific mortality, (%)
Alive
93 (33.9%)
11,445 (18.0%)
32 (51.6%)
56 (28.7%)
61 (28.8%)
11,389 (18.0%)
<0.001
Cancer death
154 (56.2%)
39,845 (62.8%)
30 (48.4%)
126 (64.6%)
124 (58.5%)
39,719 (62.7%)
<0.001
Noncancer death
27 (9.9%)
12,207 (19.2%)
0 (0.0%)
13 (7.7%)
27 (12.7%)
12,194 (19.3%)
<0.001
fHCC = fibrolamellar hepatocellular carcinoma; = number; NS = not statistically significant with value > 0.05; SD = standard deviation; data presented for patients with available information only.
